LBP Antibody (M300-19) Summary
The antibody reacts with the LBP antigen.
The monoclonal antibody M330-19 reacts highly specific with mouse natural and recombinant LBP. The antibody is a type I antibody blocking the LPS binding to LBP. LPS binding protein (LBP) is an approximately 60 kDa acute phase protein that is produced by hepatocytes. This protein strongly binds to LPS and has been shown to play an important role in the handling of LPS by the host. A number of functions of LBP have been reported. First, LBP transfers LPS to the LPS receptor CD14 on mononuclear phagocytes, leading to an 100-1,000-fold increased sensitivity of the cells to LPS. Furthermore, LBP can enhance the response of CD14 negative cells by acceleration of LPS binding to soluble CD14, a complex that stimulates these cells. Next, LBP transfers LPS into High Density Lipoprotein (HDL), which effectively neutralizes its biological potency. LBP was demonstrated to protect mice from septic shock caused by LPS or gram negative bacteria.
IgG2a
Monoclonal
Rat
LBP
Protein A or G purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
Applications/Dilutions
- Western Blot 1:100-1:2000
The antibody can be used for functional studies in vitro and in vivo aimed at blocking LBP. Furthermore the antibody is useful for immuno assays and for Western blotting.For Western blotting dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:10. For neutralization of biological activity
Packaging, Storage & Formulations
Store at 4C. Do not freeze.
PBS containing 0.1% BSA
0.02% Sodium Azide
Protein A or G purified
Alternate Names for LBP Antibody (M300-19)
- LBP
- lipopolysaccharide binding protein
- lipopolysaccharide-binding protein
- LPS-binding protein
- MGC22233
Background
The protein encoded by this gene is involved in the acute-phase immunologic response to gram-negative bacterial infections. Gram-negative bacteria contain a glycolipid, lipopolysaccharide (LPS), on their outer cell wall. Together with bactericidal permeability-increasing protein (BPI), the encoded protein binds LPS and interacts with the CD14 receptor, probably playing a role in regulating LPS-dependent monocyte responses. Studies in mice suggest that the encoded protein is necessary for the rapid acute-phase response to LPS but not for the clearance of LPS from circulation. This protein is part of a family of structurally and functionally related proteins, including BPI, plasma cholesteryl ester transfer protein (CETP), and phospholipid transfer protein (PLTP). Finally, this gene is found on chromosome 20, immediately downstream of the BPI gene. [provided by RefSeq]
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.